Inflammatory conditions decrease CD36 expression and CD36-mediated <i>Pf</i>PEs phagocytosis through downregulation of PPARγ. by David Olagnier (205583)

Rhodomyrtone decreases expression of inflammatory transcripts by TNF-α+IL-17A stimulated in skin organ cultures. by Julalak Chorachoo (5855852)

“…<p>Skin biopsies were pre-treated with 400 ng/ml rhodomyrtone 6 h before stimulation with 10 ng/ml TNF-α and 20 ng/ml IL-17A. Rhodomyrtone treatment decreases production of <i>DEFB4</i>, <i>IL1B</i>, <i>IL17C</i>, <i>IL36G</i>, <i>LCN2</i>, <i>PI3</i>, <i>S100A7</i>, and <i>S100A8</i> transcripts as measured by qRT-PCR at 72 h. …”

Compound C treatment decreases hTERT promoter activity, but AMPK activators do not increase the activity. by Daum Jo (6009578)

Removal of ascending depressor nerve abolished acute hypoxia-induced increases in RSNA, while enhanced the decrease in ABP in both control and HIH rats. by Fang Cui (313685)

Ivermectin significantly decreases <i>L</i>. <i>loa</i> mf in BALB/c mice. by Rene Bilingwe Ayiseh (6900296)

Decreased IL-17A expression following <i>i</i>NKT cell activation <i>in vivo</i>. by Jinhong Wu (424170)

C/EBPε-deficient mice have decreased PMNs but develop equivalent hypoxemia and edema with VILI. by Heather D. Jones (476855)

Afzelin treatment protects HaCaT cells against the UVB-induced decrease in cell viability by inhibiting p38 MAPK and JNK activity. by Seoung Woo Shin (405763)

<i>A</i>, HDACi-mediated decrease in CHK1 precedes apoptosis. by William Brazelle (358865)

HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model by Thaiz F. Borin (4107397)

“…The ability of tumor cells to modulate TME and to escape immune-mediated attack by releasing immunosuppressive cytokines has become a hallmark of breast cancer. Our study shows the effect of IV formulation of HET0016 (HPßCD-HET0016) a selective inhibitor of 20-HETE synthesis, administered intravenously in immune-competent in vivo mouse model of murine breast cancer. 4T1 luciferase positive cells were implanted to the mammary fat pad in Balb/c mice. …”

A decrease in SUMO-conjugated proteins accompanies <i>Shigella</i> infection. by Saima M. Sidik (590022)

Demographic information and treatment history for all participants (N = 20) in the Scania aTBS implementation study (SATIS) at inclusion. by Marcus Persson (20496333)

Enrichment of TICs decreases PP2A activity and increases Hsp27 activation in other solid tumors. by Shih-Pei Lin (117914)

Aliskiren decreases fibrosis markers and inhibits changes in apoptosis markers induced by peritoneal dialysis fluids (PDFs) in rat peritoneal mesothelial cells (PMCs). by Juan Pérez-Martínez (324784)

HSP90B1 and CALM1 were increased, but ANXA6 and TPM2 were decreased, in tissues from patients with PCOS. by Li Li (14993)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

CPA treatment decreases cell death, Müller cell activation and microglial infiltration. by Manuel Soliño (5410001)

“…Scale bar: 20μm. C-D) Microphotograph of GFAP immunostained sections of CPA treated eye (C) and Control eye (D). …”

Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo. by Rebecka Hellsten (348459)

“…The proportion of ALDH+ cells is expressed as mean ± SEM (n = 2–4). The proportion of ALDH+ DU145 cells were significantly decreased by galiellalactone at the concentrations 10 µM (p = 0.0060), 25 µM (p = 0,0013) and 50 µM galiellalactone (p<0,0001). …”

Nitrotyrosination of gp34 significantly decreases both its binding affinity and stabilization capacity of the H-2K^b complex. by Chaithanya Madhurantakam (329447)

Simultaneous ablation of Syt1 and Syt7 decreases the RRP size at inhibitory synapses: Rescue by WT but not mutant Syt1 or Syt7. by Taulant Bacaj (803415)

“…</b> Simultaneous ablation of Syt1 and Syt7 decreases the RRP size of inhibitory synapses in a manner that is rescued by WT Syt7 (Syt1^WT) but not Syt7 with mutations in the top C2 domain sequences containing the Syt7 Ca²⁺ binding sites (Syt7^C2A*^B*). …”